Edition:
United Kingdom

Nicox SA (NCOX.PA)

NCOX.PA on Paris Stock Exchange

8.82EUR
2:30pm BST
Change (% chg)

€0.00 (+0.06%)
Prev Close
€8.81
Open
€8.82
Day's High
€8.94
Day's Low
€8.79
Volume
35,782
Avg. Vol
105,318
52-wk High
€13.68
52-wk Low
€7.65

Chart for

About

Nicox SA is a France-based international ophthalmic company. It is engaged in the field of the research, development and future commercialization of investigational drugs for ophthalmological diseases. The Company’s aim is to build a portfolio of therapeutic products addressing the needs of eye care practitioners and patients.... (more)

Overall

Beta: 0.37
Market Cap(Mil.): €264.46
Shares Outstanding(Mil.): 29.58
Dividend: --
Yield (%): --

Financials

  NCOX.PA Industry Sector
P/E (TTM): -- 28.56 32.59
EPS (TTM): -0.37 -- --
ROI: -5.93 13.05 12.60
ROE: -7.13 14.79 14.49

BRIEF-Nicox Q1 Net Revenue At 0.075 Million Euros

* AS OF MARCH 31, 2018, THE GROUP HAD CASH AND CASH EQUIVALENTS OF €36.3 MILLION AS COMPARED WITH €41.4 MILLION AT DECEMBER 31, 2017

04 May 2018

BRIEF-Nicox Opening Of U.S. Development Office In Research Triangle Park, North Carolina

* REG-NICOX: OPENING OF U.S. DEVELOPMENT OFFICE IN RESEARCH TRIANGLE PARK, NORTH CAROLINA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

25 Apr 2018

BRIEF-Nicox Announces Increase In Royalties From Bausch + Lomb For Vyzulta

* REG-NICOX ANNOUNCES IMPROVED FINANCIAL TERMS FROM BAUSCH + LOMB FOR VYZULTA

14 Mar 2018

BRIEF-Nicox Provides 2018 Outlook And 2017 Estimated Financial Results

* ZERVIATETM (CETIRIZINE OPHTHALMIC SOLUTION), 0.24%, U.S. LAUNCH PLANNED BY PARTNER EYEVANCE PHARMACEUTICALS FOR THE 2018 FALL ALLERGY SEASON

06 Mar 2018

BRIEF-Nicox Updates on Drug Development And Outlines 2018 Activities

* RESOURCES IN 2018 WILL BE FOCUSED ON ADVANCING NICOX'S PIPELINE CANDIDATES NCX 470 AND NCX 4251 TOWARDS MID-STAGE CLINICAL DEVELOPMENT

19 Dec 2017

Earnings vs. Estimates